Drug Detail

Information about INCB24360

Generic Name
IND	INCB24360
Brand Name (US)
Manufacturer	Incyte
Drug Type	Small molecule
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	Immune system
Strategy	Immunotherapy
Drug Category	IDO1 inhibitor

High IDO expression has been found in GIST tumors. IDO promotes the development, stabilization and activation of T reg cells and suppresses effector T cells (it acts as an immune system suppressor).
INCB24360 is an orally bioavailable small molecule inhibitor of IDO1 that has nanomolar potency in both biochemical and cellular assays, potent activity in enhancing T lymphocyte, dendritic cell and natural killer cell responses in vitro, with a high degree of selectivity.
A Phase I dose-escalation trial demonstrated that INCB24360 results in greater than 90 percent inhibition of IDO1 activity at generally well-tolerated doses.